Li Jia, Yang Xue-Zhi, Wang Yi-Ping, Chen Xiao-Li, Zhang Xu
Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
J Stroke Cerebrovasc Dis. 2017 Jul;26(7):e133-e137. doi: 10.1016/j.jstrokecerebrovasdis.2017.04.009. Epub 2017 May 2.
Embolic stroke of undetermined source (ESUS) is a new clinical construct. It signifies that the embolus in the thromboembolic ischemic stroke is of unknown origin. The anticoagulants are usually prescribed for antithrombotic prophylaxis, but whether it is appropriate for all patients with ESUS is still unknown.
In this article, we describe 3 cases of ESUS, all of whose antithrombotic therapy was antiplatelet medication, and the 3 patients had no recurrence on 3- to 7-month follow-up.
Because there was no obvious risk factor found in these ESUS cases, the recurrence risk is difficult to evaluate, and the optimum means of secondary prevention are still unknown. Hence, many aspects warrant resolution.
不明来源栓塞性卒中（ESUS）是一种新的临床概念。它表明血栓栓塞性缺血性卒中中的栓子来源不明。抗凝剂通常用于抗血栓预防，但对于所有ESUS患者是否适用仍不清楚。
在本文中，我们描述了3例ESUS病例，所有患者的抗血栓治疗均为抗血小板药物，且3例患者在3至7个月的随访中均未复发。
由于这些ESUS病例中未发现明显的危险因素，复发风险难以评估，二级预防的最佳方法仍不清楚。因此，许多方面有待解决。
